A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

This observational study is monitoring people with type 2 diabetes who are starting a combination pill of dapagliflozin and pioglitazone (a medication to lower blood sugar and also affect fat metabolism in the liver). Researchers want to track whether this medication reduces the risk of developing non-alcoholic fatty liver disease (NAFLD). **You may be eligible if...** - You have type 2 diabetes - You are starting or about to start the dapagliflozin/pioglitazone combination medication - You provide written consent for your data to be used **You may NOT be eligible if...** - You have previously taken this medication combination before - You are expected to need insulin during the study period Talk to your doctor to see if this trial is right for you.